BMO Capital analyst Simeon Siegel maintains Nike (NYSE:NKE) with a Outperform and raises the price target from $160 to $174.
UPDATE: Merck Press Release Confirms Clinical Holds On Studies Evaluating Islatravir
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has placed clinical holds on the investigational new drug applications (INDs) for the